Delivery Order SPE2DB22D1017-SPE2DB25FG8CJ
- Not listed
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $15,470.70 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical products...
- The Defense Logistics Agency awarded a $20,290.04 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency awarded a $46,389.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL pen auto-injectors on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a $16,346.89 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of July 28, 2025. This firm fixed-price contract, which was competitively awarded without set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a Delivery Order valued at $10,256.76 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, firm fixed-price contract requires delivery by July 23, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The award carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA....
- The Defense Logistics Agency awarded a $28,192.03 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 22, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8CJDelivery Order
The Defense Logistics Agency awarded a $26,836.77 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 24, 2025, with completion targeted for July 25, 2025. This firm fixed-price contract represents a single delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was not set-aside and resulted from competitive procurement, reflecting AmerisourceBergen's established capability as a critical pharmaceutical supplier within the federal medical supply chain. The pharmaceutical will be delivered to the company's corporate headquarters location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a specialty biologic medication used primarily to treat moderate-to-severe atopic dermatitis, asthma, and other allergic and inflammatory conditions. This delivery order supports the Defense Health Agency's medical supply requirements for military healthcare systems and beneficiaries. AmerisourceBergen's comprehensive IDC with DLA enables flexible procurement of brand-name and generic pharmaceuticals, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic categories, positioning the distributor as a key vendor for the department's global pharmaceutical support operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.8k | 7/24/25 |